Curated News
By: NewsRamp Editorial Staff
July 22, 2026

Oncotelic and Sapu Nano Publish Preclinical Data for Sapu003 Deciparticle Everolimus

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Oncotelic's Sapu003 overcomes oral everolimus limitations, potentially capturing market share in advanced solid tumor treatments.
  • Sapu003 is an intravenous Deciparticle formulation of everolimus, with published ADME, PK, toxicology, and cGMP data supporting Phase 1 trials.
  • Sapu003 reduces gastrointestinal side effects, improving quality of life for advanced solid tumor patients undergoing therapy.
  • The Deciparticle platform transforms hydrophobic drugs like everolimus into IV medicines, expanding treatment options for hard-to-treat cancers.

Impact - Why it Matters

This news matters because Sapu003 represents a potential breakthrough in cancer treatment by transforming everolimus into an intravenous formulation, which could improve drug delivery and reduce side effects compared to oral administration. The comprehensive preclinical data package supports ongoing clinical trials, offering hope for patients with advanced solid tumors who may benefit from more effective and tolerable therapies. Additionally, the validation of Oncotelic's Deciparticle platform opens doors for other hydrophobic drugs to be reformulated as intravenous medicines, potentially expanding treatment options across oncology.

Summary

Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, has announced the publication of a peer-reviewed study in Biomedicines that details preclinical data for Sapu003, its intravenous Deciparticle(TM) formulation of everolimus. The study covers absorption, distribution, metabolism, excretion (ADME), pharmacokinetics, tissue distribution, GLP toxicology, and cGMP manufacturing data, supporting an ongoing Phase 1 clinical trial in patients with advanced solid tumors. The formulation aims to overcome pharmacokinetic limitations of oral everolimus while preserving its metabolic profile, and the published findings show reduced gastrointestinal drug exposure, no treatment-related gastric pathology in repeat-dose GLP toxicology studies, and a reproducible cGMP manufacturing process for clinical production.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, addressing high-unmet-need cancers and rare pediatric indications. The company owns 45% of GMP Bio, a joint venture under CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 U.S. patents. Oncotelic also develops PDAOAI, a proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing, in partnership with SAPU Bio and TechForce Robotics. The company's newsroom provides updates on OTLC at https://ibn.fm/OTLC.

The press release was distributed by BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which offers press distribution via InvestorWire, editorial syndication to 5,000+ outlets, and enhanced press release services. BMW focuses on biotechnology, biomedical sciences, and life sciences sectors, and can be reached at https://www.BioMedWire.com. For the full press release, visit https://ibn.fm/hocuZ.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic and Sapu Nano Publish Preclinical Data for Sapu003 Deciparticle Everolimus

blockchain registration record for this content.